glioma CSF exosomal liquid biopsy marker sequencing

Omics technology research of glioma early diagnosis and prognosis evaluation

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032547

Enrollment

Unknown

Registered

2020-05-02

Start date

2017-01-01

Completion date

Unknown

Last updated

2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioma

Interventions

Gold Standard:Pathological diagnosis

Index test:cerebrospinal&#32

fluid&#32

exosomal&#32

RNA

Eligibility

Sex/Gender

All

Age

14 Years to 72 Years

Inclusion criteria

Inclusion criteria: Patients of glioma accepted operative treatment in the department of neurosurgery qilu hospital shandong university during January 2017 - October 2019, need to have pathological diagnosis, complete imaging and clinical data, tumor tissue specimens and blood specimens, preoperative and postoperative cerebrospinal fluid specimens and other requirements.

Exclusion criteria

Exclusion criteria: none glioma patient, do not obtained CSF or tumor specimens

Design outcomes

Primary

Measure	Time frame
whole-transcriptome sequencing of glioma and CSF;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactGang Li

Qilu hospital Shandong University

ligangqiluhospital@163.com+86 13606373098

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026